Email this article Oncolytic Activity of the Vaccine Strain of Type 3 Poliovirus on the Model of Rat Glioma C6 Cells
- Authors: Sosnovtseva A.O.1,2, Zheltukhin A.O.2, Lipatova A.V.2, Chumakov P.M.2,3, Chekhonin V.P.1,4
-
Affiliations:
- V. P. Serbsky National Medical Research Center for Psychiatry and Narcology, Ministry of Health of the Russian Federation
- V. A. Engelhardt Institute of Molecular Biology, Russian Academy of Science
- M. P. Chumakov Federal Research Center for Research and Development of Immunobiological Products, Russian Academy of Sciences
- N. I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation
- Issue: Vol 167, No 1 (2019)
- Pages: 111-115
- Section: Methods
- URL: https://journal-vniispk.ru/0007-4888/article/view/241494
- DOI: https://doi.org/10.1007/s10517-019-04472-6
- ID: 241494
Cite item
Open Access
Access granted
Subscription Access
Abstract
Rat glioma cell line C6 expressing human poliovirus receptor (PVR) and susceptible to polioviruses (C6-PVR-BFP) was used to produce a clone with knockout of IFNα/β (Ifnar1) receptor subunit 1 gene (Ifnar1). The sensitivity of C6-PVR-BFP cells to the vaccine strain of poliovirus type 3 (PV3) depended on the signaling pathways of the cell response to type 1 IFN. Using the model of subcutaneous tumor xenografts, we demonstrated oncolytic activity of PV3 against C6-PVR-BFP cells that depended on the expression of PVR and increased considerably upon disturbances in IFN response pathways.
About the authors
A. O. Sosnovtseva
V. P. Serbsky National Medical Research Center for Psychiatry and Narcology, Ministry of Health of the Russian Federation; V. A. Engelhardt Institute of Molecular Biology, Russian Academy of Science
Author for correspondence.
Email: aososnovtceva@gmail.com
Russian Federation, Moscow; Moscow
A. O. Zheltukhin
V. A. Engelhardt Institute of Molecular Biology, Russian Academy of Science
Email: aososnovtceva@gmail.com
Russian Federation, Moscow
A. V. Lipatova
V. A. Engelhardt Institute of Molecular Biology, Russian Academy of Science
Email: aososnovtceva@gmail.com
Russian Federation, Moscow
P. M. Chumakov
V. A. Engelhardt Institute of Molecular Biology, Russian Academy of Science; M. P. Chumakov Federal Research Center for Research and Development of Immunobiological Products, Russian Academy of Sciences
Email: aososnovtceva@gmail.com
Russian Federation, Moscow; Moscow
V. P. Chekhonin
V. P. Serbsky National Medical Research Center for Psychiatry and Narcology, Ministry of Health of the Russian Federation; N. I. Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation
Email: aososnovtceva@gmail.com
Russian Federation, Moscow; Moscow
Supplementary files
